Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
October 14th, 2019
6.3K views
Neuroendocrine tumors (NETs) originate from neuroendocrine cells of the neural crest. They are slow growing and challenging to culture. We present an alternative strategy to grow NETs from the small bowel by culturing them as spheroids. These spheroids have small bowel NET markers and can be used for drug testing.
Overview
This study presents a novel 3D culture protocol for growing well-differentiated small bowel neuroendocrine tumors (SBNETs) from patient samples. This method allows for drug testing within three weeks, overcoming the limitations of traditional cell line establishment.
Key Study Components
Area of Science
- Neuroendocrine tumors
- Cell culture techniques
- Drug testing methodologies
Background
- Neuroendocrine tumors (NETs) arise from neuroendocrine cells.
- SBNETs are slow-growing and difficult to culture.
- Established cell lines are scarce and not widely available.
- 3D culture techniques can enhance propagation and testing.
Purpose of Study
- To develop a reliable method for culturing SBNETs.
- To facilitate drug testing on cultured NETs.
- To provide a protocol applicable to other types of neuroendocrine tumors.
Methods Used
- Resected patient SBNET samples were cut into five millimeter cubes.
- Samples were stored in DMEM F12 medium for transportation.
- 3D culture protocol was implemented for cell growth.
- Drug testing was conducted within three weeks of culturing.
Main Results
- 3D cultures exhibited small bowel NET markers.
- Drug testing was successfully performed on cultured spheroids.
- The method showed potential for application to pancreatic NETs.
- Results indicate a faster alternative to traditional cell line establishment.
Conclusions
- The 3D culture method is effective for SBNET propagation.
- This approach can accelerate drug testing timelines.
- Further research may expand its application to other NETs.
Frequently Asked Questions
What are neuroendocrine tumors?
Neuroendocrine tumors (NETs) originate from neuroendocrine cells and can be found in various organs.
Why are SBNETs difficult to culture?
SBNETs are slow-growing and have limited availability of established cell lines for research.
What is the advantage of 3D culture?
3D culture allows for more natural cell growth and quicker drug testing compared to traditional methods.
How long does it take to test drugs using this method?
Drug testing can be conducted within three weeks of culturing the spheroids.
Can this method be applied to other types of NETs?
Yes, the method can potentially be applied to other neuroendocrine tumors, such as those from the pancreas.
Executive Industry Relevance
Establishing reliable preclinical models for rare cancers like small bowel neuroendocrine tumors (SBNETs) remains a significant bottleneck in oncology drug development due to limited availability of patient-derived cell lines and slow proliferation rates. This 3D spheroid culture method enables rapid generation of physiologically relevant SBNET models from resected tumors, supporting mechanistic de-risking and target validation within a three-week timeframe. By preserving neuroendocrine marker expression and drug response characteristics, the approach enhances predictive confidence in early discovery and supports portfolio prioritization for NET-targeted therapies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using patient-derived SBNET spheroids that retain neuroendocrine marker expression (synaptophysin, chromogranin A, SSTR2).
- Operational Value: Provides a reproducible 3D culture system for functional target validation without the extended timelines required for traditional cell line establishment.
- Predictive Value: Supports biological de-risking by maintaining tumor microenvironment-like conditions through extracellular matrix encapsulation.
Screening & Assay Development
- Assay Readiness: Generates standardized SBNET spheroids suitable for compound screening, with drug testing feasible within three weeks of culture initiation.
- Quantitative Outputs: Allows measurement of cytotoxic responses via structural changes (e.g., grape-like morphology) and apoptosis/necrosis markers following treatment with agents like rapamycin.
- Scalability & Reuse: Spheroids can be cryopreserved, shipped in ECM, and re-established in recipient labs, enabling cross-laboratory assay standardization.
Translational & Preclinical Research
- Disease Relevance: Maintains key SBNET biomarkers in spheroid culture, supporting translational continuity from discovery to preclinical validation.
- Mechanistic De-risking: Enables evaluation of mTOR pathway inhibitors in a clinically relevant 3D NET model prior to in vivo studies.
- Risk-Adjusted Advancement: Facilitates early go/no-go decisions based on spheroid drug response profiles, reducing late-stage failure risk.
Pipeline & Workflow Integration
The method integrates into the discovery workflow by providing a rapid preclinical model for target validation and lead identification, bridging early biology with mechanistic screening before in vivo validation.
- Discovery Biology: Supports hypothesis testing and pathway clarification using patient-derived SBNET spheroids that reflect native tumor biology.
- Screening: Enables assay-ready spheroid production for evaluating compound libraries with quantifiable cytotoxicity readouts.
- Analytics: Generates immunofluorescence and morphological data to assess target engagement and phenotypic responses.
- Translational Research: Preserves neuroendocrine phenotype, allowing biomarker-aligned studies from spheroid to preclinical models.
- Enterprise Reuse: Establishes a shareable, reproducible SBNET spheroid platform applicable across discovery teams and external collaborators.
Operational & Enterprise Impact
- Scientific Value: Enhances target validation confidence by preserving neuroendocrine identity and drug responsiveness in a 3D patient-derived model.
- Operational Value: Delivers standardized, scalable spheroid cultures with defined growth kinetics (doubling in ~14 days) and compatibility with immunofluorescence workflows.
- Strategic Value: Accelerates preclinical timelines, enabling faster mechanistic de-risking and improved capital efficiency in rare cancer drug discovery.
- Portfolio Impact: Informs risk-adjusted prioritization of NET-targeted candidates through early phenotypic screening in a clinically relevant model.
Implementation Considerations
- Requires expertise in sterile tissue processing, enzymatic digestion, and 3D extracellular matrix handling.
- Dependent on access to centrifugation, cell straining, fluorescence microscopy, and standard cell culture incubators.
- Necessitates standardized wash medium and ECM preparation across sites to ensure spheroid integrity and marker retention.
- Requires optimization of antibody panels and permeabilization conditions for consistent immunofluorescence detection of SBNET markers.
- Limited by the availability of fresh resected SBNET tissue and the need to avoid over-digestion during collagenase/DNase treatment.
Biopharma FAQs
Why does marker confirmation matter for target validation in SBNET spheroids?
Confirming expression of neuroendocrine markers like synaptophysin, chromogranin A, and SSTR2 ensures the spheroids retain the phenotypic identity of the original tumor, which is essential for valid target hypothesis testing and mechanistic de-risking in early discovery.
How does isolating viable single cells enable spheroid formation in this protocol?
Isolating viable SBNET cells through enzymatic digestion, filtration, and centrifugation removes fibroblasts and debris, allowing uniform encapsulation in extracellular matrix to form reproducible spheroids that mimic the tumor microenvironment.
What quantitative measurements enable cytotoxicity assessment in SBNET spheroids?
Cytotoxicity is assessed through morphological changes such as grape-like structuring and apoptosis/necrosis formation after five days of rapamycin treatment, providing a visual and structural readout of drug response.
Why do replication requirements matter for cross-functional collaboration in spheroid workflows?
Reproducible spheroid generation and consistent marker expression across batches ensure that discovery, screening, and preclinical teams can rely on standardized models for comparable data sharing and decision-making.
What statistical analysis capabilities are required before implementing drug testing in SBNET spheroids?
Basic comparative analysis of treated versus control spheroid morphology and marker retention is sufficient to evaluate drug effects, enabling go/no-go decisions without requiring complex statistical modeling in early screening stages.
Chapters in this video
0:04
Title
0:44
Small Bowel Neuroendocrine Tumor (SBNET) Collection and Cell Dissociation
2:10
Culture of SBNET as Tumor Spheroids in ECM
4:02
Characterization of SBNET Spheroids by Immunofluorescence
5:50
Splitting SBNET Spheroids
7:23
Results: Immunofluorescence Imaging and Drug Testing of SBNET Spheroids
9:02
Conclusion
